

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Dow Pharmaceutical Sciences, Inc.	04/15/2011
RECEIVING PARTY DATA	
Name:	Xenon Pharmaceuticals Inc.
Street Address:	3650 Gilmore Way
City:	Burnaby
State/Country:	CANADA
Postal Code:	V5G 4W8
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	61308759
PCT Number:	US1126359
CORRESPONDENCE DATA	
Fax Number:	(206)682-6031
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	2066224900
Email:	carolw@seedip.com
Correspondent Name:	Carol J. Roth
Address Line 1:	701 Fifth Avenue
Address Line 2:	Suite 5400
Address Line 4:	Seattle, WASHINGTON 98104-7092
ATTORNEY DOCKET NUMBER:	980057.481PC_3_OF_3
NAME OF SUBMITTER:	Carol J. Roth
Total Attachments: 4 source=Dow to Xenon#page1.tif source=Dow to Xenon#page2.tif source=Dow to Xenon#page3.tif source=Dow to Xenon#page4.tif	

CH \$80.00 61308759

ASSIGNMENT

WHEREAS, **Xenon Pharmaceuticals Inc.** (hereinafter referred to as ASSIGNEE), a corporation incorporated under the laws of Canada, having a place of business at 3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8, is desirous of acquiring the entire right, title and interest in and to the invention entitled "**PHARMACEUTICAL COMPOSITIONS OF SPIRO-OXINDOLE COMPOUND FOR TOPICAL ADMINISTRATION AND THEIR USE AS THERAPEUTIC AGENTS**," as described and claimed in the PCT international application as filed in the U.S. Receiving Office of the PCT on February 25, 2011, which was assigned PCT International Application No. PCT/US2011/026359, and which claims priority to U.S. Provisional Patent Application No. 61/308,759, filed February 26, 2010;

WHEREAS, **Dow Pharmaceutical Sciences, Inc.** (hereinafter referred to as ASSIGNOR), is a Delaware corporation having a place of business at 1330 Redwood Way, Petaluma, California 94954;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby sells, assigns and transfers unto said ASSIGNEE its entire right, title and interest in and to said U.S. Provisional Application and the invention(s) disclosed therein, and any and all letters patent(s) which claim priority to said U.S. Provisional Application and any and all letters patent(s) which claim the invention(s) disclosed therein and which may be granted in the United States of America and its territorial possessions and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said U.S. Provisional Application to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, said invention, U.S. Provisional Application and all letters patent(s) on said invention or claiming priority to said U.S. Provisional Application to be held and enjoyed by ASSIGNEE and its successors and assigns for their use and benefit as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, transfer and sale not been made. ASSIGNOR hereby authorizes and requests the U.S. Commissioner of Patents and Trademarks to issue all letters patent on said invention to ASSIGNEE. ASSIGNOR agrees to execute all instruments and documents required for the making and prosecution of applications for United States and foreign letters patent on said invention, for litigation regarding said letters patent, or for the purpose of protecting title to said invention or letters patent therefor. ASSIGNEE will be solely responsible for any costs related to this assignment and the recording of this assignment in the U.S. and any foreign countries.

Xenon Pharmaceuticals Inc.

By: Tarek S. Mansour

Print Name: Tarek S. Mansour

Title: Executive Vice President, Research & Development

Date: May 6, 2011

Province of British Columbia)
Country of Canada) ss.


I hereby certify that I know or have satisfactory evidence that **Tarek S. Mansour**, Executive Vice President, Research & Development of Xenon Pharmaceuticals Inc., is the person who appeared before me, and said person acknowledged that he signed this instrument, on oath stated that he was authorized to execute the instrument on behalf of Xenon Pharmaceuticals Inc., a corporation organized and existing according to the laws of Canada, and acknowledged it to be his free and voluntary act for the uses and purposes mentioned in the instrument.

Dated May 6, 2011

Signature of Notary Public Thong Trinh

Printed Name THONG N. TRINH

My Commission is for as long as I remain a practicing member of the Law Society of British Columbia.



Dow Pharmaceutical Sciences, Inc.

By: *Darlene Walley*

Print Name: Darlene Walley

Title: Vice President & General Manager

Date: April 15, 2011

City of _____)
County of _____)
State of _____)

ss.

I certify that I know or have satisfactory evidence that _____
is the person who appeared before me, and said person acknowledged that he signed this instrument and
acknowledged it to be his free and voluntary act for the uses and purposes mentioned in the instrument.

Dated _____

Signature of
Notary Public _____

Printed Name _____

My appointment expires _____

980057.481PC C48.6-WO 1855389_1.DOCX

*SEE ATTACHED
Certificate*

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

State of California

County of SONOMA


On April 15, 2011 before me, PATTY R. IRVING, Notary Public

personally appeared DARLENE R. WALLEY

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.



Place Notary Seal Above

Signature Patty R. Irving
Signature of Notary Public

OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

Description of Attached Document

Title or Type of Document: ASSIGNMENT

Document Date: _____ Number of Pages: 3

Signer(s) Other Than Named Above: TAREK S. MANSOUR

Capacity(ies) Claimed by Signer(s)

Signer's Name: DARLENE R. WALLEY

- Individual
- Corporate Officer — Title(s): _____
- Partner — Limited General
- Attorney in Fact
- Trustee
- Guardian or Conservator
- Other: GENERAL MANAGER

Signer Is Representing: DOW PHARMACEUTICAL SCIENCES



Signer's Name: _____

- Individual
- Corporate Officer — Title(s): _____
- Partner — Limited General
- Attorney in Fact
- Trustee
- Guardian or Conservator
- Other: _____

Signer Is Representing: _____

